The PD‐L1‐positive rate in HRS cells of de novo CHL is more than 80%, and anti‐PD‐1 antibody therapy for the treatment of de novo CHL is now being adopted.15, 16, 17, 24. This evidence concerns the gene CD274 and classic Hodgkin lymphoma.